Opinion|Videos|October 2, 2024
Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs
Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you share some of the biggest unmet need(s) or treatment gaps that still exist for patients with breast cancer who are receiving antibody-drug conjugates and some practice pearls you wish to share with your community colleagues?
Advertisement
Related to this article
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5